American Century Companies Inc. Raises Stock Position in Kenvue Inc. $KVUE

American Century Companies Inc. raised its stake in Kenvue Inc. (NYSE:KVUE) by 22.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 37,046,660 shares of the company’s stock after purchasing an additional 6,781,640 shares during the quarter. Kenvue accounts for 0.3% of American Century Companies Inc.’s portfolio, making the stock its 29th biggest position. American Century Companies Inc. owned 1.93% of Kenvue worth $601,267,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Salomon & Ludwin LLC bought a new stake in Kenvue during the 3rd quarter valued at about $25,000. NBT Bank N A NY boosted its position in shares of Kenvue by 180.3% in the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after purchasing an additional 1,006 shares during the period. Cornerstone Planning Group LLC boosted its stake in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after purchasing an additional 1,361 shares during the period. Golden State Wealth Management LLC increased its holdings in Kenvue by 150.1% in the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after acquiring an additional 1,190 shares during the last quarter. Finally, Trust Co. of Vermont boosted its stake in Kenvue by 50.9% during the third quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock valued at $39,000 after buying an additional 804 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Activity

In related news, Director Jeffrey C. Smith purchased 3,200,000 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were purchased at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the purchase, the director owned 27,307,632 shares of the company’s stock, valued at $474,333,567.84. The trade was a 13.27% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.68% of the stock is owned by company insiders.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $19.11 on Friday. The company has a market capitalization of $36.62 billion, a PE ratio of 24.81, a price-to-earnings-growth ratio of 4.35 and a beta of 0.59. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.96. The company’s fifty day moving average price is $17.72 and its 200 day moving average price is $17.56. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $25.17.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The business had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. During the same period in the prior year, the company posted $0.26 EPS. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.3%. The ex-dividend date of this dividend was Wednesday, February 11th. Kenvue’s dividend payout ratio is presently 107.79%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of research analyst reports. Edward Jones lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Jefferies Financial Group lowered shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. UBS Group upped their price objective on Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. Barclays lifted their price objective on shares of Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Monday, November 10th. Finally, Zacks Research raised shares of Kenvue from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. Three research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $19.50.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.